Study finds lab-created antibody effective in preventing severe respiratory illness in infants
A monoclonal antibody -- a protein created in a lab which mimics the work of a natural antibody -- could be highly effective in preventing severe RSV-- Respiratory syncytial virus, a respiratory infection and major cause of serious illness in infants, according to a research.
Study findings
Findings of the study, published in The Lancet Child and Adolescent Health journal, show that injecting infants with the antibody 'nirsevimab' reduces risk of RSV-related hospitalisations by 83 per cent and intensive care admissions by 81 per cent. Infant immunisation programmes could, therefore, help address the health and economic burden due to RSV in the high-risk period following birth, a team of researchers from Canada and the US said. RSV, or respiratory syncytial virus, is one of the leading causes of serious respiratory ill-health in the early years of one's life, and is usually prevalent during early winter months.
Globally, the condition is estimated to cause 36 lakh hospitalisations a year among children aged under five, according to the World Health Organization.
Nirsevimab was approved in 2023 by regulatory agencies, including the US' Food and Drug Administration and European Medicines Agency, after the lab-created antibody was found to be safe and effective in clinical trials.
Effectiveness of nirsevimab
Through national programmes, infants in high-income countries, such as in the US and European Union, have been injected with nirsevimab. The researchers said that efficacy of nirsevimab seen in the controlled settings of a clinical trial may not fully reflect how the lab-created antibody performs in real-world settings.
Real-world effectiveness studies are essential to evaluate the effectiveness of nirsevimab across diverse infant populations and clinical settings, the team added. For this study, the researchers analysed 27 previously published studies, which were conducted during the RSV seasons of 2023-2024 across five countries -- France, Italy, Luxembourg, Spain and the US. The team mainly focussed on infants aged under 12 months.
"Nirsevimab is highly effective in preventing RSV-related outcomes in infants, with a pooled real-world effectiveness of 83 per cent against hospitalisation, 81 per cent against ICU admission, and 75 per cent against LRTI (lower respiratory tract infections)," the authors wrote.
The lab-created antibody was also found to be more effective among infants aged over three months, compared to those aged under three months.
Monoclonal is an antibody, not a vaccine
The researchers noted that nirsevimab is not a vaccine, despite being delivered as an injection.
A monoclonal antibody is created in a lab to mimic how an antibody works, whereas a vaccine empowers the body's immune system to produce an immune response, which involves creating antibodies, they said.
The findings indicate that the benefits of nirsevimab seen in clinical trials could be translated into real-world settings, potentially reducing the burden of RSV disease among infants and use of healthcare resources, the authors said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NDTV
3 hours ago
- NDTV
WHO Is Finalising A New Treaty To Prep For The Next Pandemic, But US Isn't Signing
On March 20, 2025, members of the World Health Organization adopted the world's first pandemic agreement, following three years of 'intensive negotiations launched by governments in response to the devastating impacts of the COVID-19 pandemic.' The U.S., however, did not participate, in part because of its intention to withdraw from the WHO. Global health experts are hailing the agreement as a historic moment. What does the agreement mean for the world, and how can it make everyone safer and more prepared for the next pandemic? The Conversation asked Nicole Hassoun, a professor at Binghamton University and executive director of Global Health Impact, to explain the pandemic accord, its prospects for advancing global health, and the significance of the U.S.'s absence from it. What will the pandemic agreement do? The accord will bolster pandemic preparation within individual countries and around the world. Countries signing onto the agreement are committing to improve their disease surveillance and grow their heath care workforces, strengthen their regulatory systems and invest in research and development. It encourages countries to strengthen their health regulations and infrastructure, improve communication with the public about pandemics and increase funding for preparation and response efforts. It also includes new mechanisms for producing and distributing vaccines and other essential countermeasures. Finally, it encourages countries to coordinate their responses and share information about infectious diseases and intellectual property so that vaccines and other essential countermeasures can be made available more quickly. The agreement will take effect once enough countries ratify it, which may take several years. Why isn't the US involved? The Biden administration was broadly supportive of a pandemic agreement and was an active participant in negotiations. Prior to Donald Trump's reelection, however, Republican governors had signed a letter opposing the treaty, echoing a conservative think tank's concerns about U.S. sovereignty. The U.S. withdrew from negotiations when President Trump signed an executive order to withdraw from the WHO on the day he was inaugurated for his second term. Why could the lack of US involvement be beneficial for the world? The lack of U.S. involvement likely resulted in a much more equitable treaty, and it is not clear that countries could have reached an agreement had the U.S. continued to object to key provisions. It was only once the U.S. withdrew from the negotiations that an agreement was reached. The U.S. and several other wealthy countries were concerned with protecting their pharmaceutical industry's profits and resisted efforts aimed at convincing pharmaceutical companies to share the knowledge, data and intellectual property needed for producing new vaccines and other essential countermeasures. Other negotiators sought greater access to vaccines and other treatments during a pandemic for poorer countries, which often rely on patented technologies from global pharmaceutical companies. While most people in wealthy countries had access to COVID-19 vaccines as early as 2021, many people in developing countries had to wait years for vaccines. How could the agreement broaden access for treatments? One of the contentious issues in the pandemic agreement has to do with how many vaccines manufacturers in each country must share in exchange for access to genetic sequences to emerging infectious diseases. Countries are still negotiating a system for sharing the genetic information on pathogens in return for access to vaccines themselves. It is important that researchers can get these sequences to make vaccines. And, of course, people need access to the vaccines once they are developed. Still, there are many more promising aspects of the agreement for which no further negotiations are necessary. For instance, the agreement will increase global vaccine supply by increasing manufacturing around the world. The agreement also specifies that countries and the WHO should work together to create a mechanism for fairly sharing the intellectual property, data and knowledge needed to produce vaccines and other essential health products. If financing for new innovation requires equitable access to the new technologies that are developed, many people in poor countries may get access to vaccines much more quickly in the next pandemic. The agreement also encourages individual countries to offer sufficient incentives for pharmaceutical companies to extend access to developing countries. If countries implement these changes, that will benefit people in rich countries as well as poor ones. A more equitable distribution of vaccines can contain the spread of disease, saving millions of lives. What more should be done, and does the US have a role to play? In my view, the best way to protect public health moving forward is for countries to sign on to the agreement and devote more resources to global health initiatives. This is particularly important given declining investment and participation in the WHO and the contraction of other international health initiatives, such as USAID. Without international coordination, it will become harder to catch and address problems early enough to prevent epidemics from becoming pandemics. It will also be imperative for member countries to provide funding to support the agreement's goals and secure the innovation and access to new technologies. This requires building the basic health infrastructure to ensure shots can get into people's arms.
Time of India
5 hours ago
- Time of India
Rare bypass surgery saves 2-year-old with Kawasaki disease in Gurgaon
Gurgaon: Surgeons at Medanta Hospital performed a rare coronary artery bypass grafting (CABG) on a two-year-old boy from Iraqi Kurdistan suffering from advanced Kawasaki disease. The child's severe coronary blockages and 25% heart function required a five-hour procedure that used both internal thoracic arteries, a method seldom applied to patients this young. Also known as mucocutaneous lymph node syndrome, Kawasaki is an inflammatory condition that affects blood vessels in young children (under the age of 5) and can severely damage the heart. This can lead to serious heart complications, with around 5% of affected children developing large coronary artery aneurysms and severe vessel narrowing. While the exact cause remains unknown, it is believed to stem from an abnormal immune response to an infection. Diagnosed with Kawasaki disease at just eight months, the child initially received treatment locally. However, his condition progressively worsened. He would get breathless, fatigued easily, and was unable to play or keep up with other children. After multiple consultations, he was referred to Medanta for advanced care. By the time he was admitted at the age of two, he was critically ill. Doctors at Medanta found his heart function dropped to just 25% (LVEF), and imaging revealed severely dilated and blocked coronary arteries. A CT coronary angiogram confirmed aneurysms and complete blockages of both left and right coronary arteries, while a PET scan showed hibernating myocardium, areas of the heart muscle receiving inadequate blood flow but still viable. Given the severity of the blockages and the child's failing heart, a team led by Dr Anil Bhan, chairman, cardiac surgery, cardiac care, Medanta, Gurgaon, opted for an exceptionally rare surgical approach, coronary artery bypass grafting using both internal thoracic arteries (ITAs), which is almost never performed on children this young. The internal thoracic arteries (ITAs) are preferred in such surgeries because they grow as the child grows and remain functional for life. Highlighting the complexity of the surgery, Dr Bhan said, "Kawasaki disease is not very rare, but advanced coronary artery involvement requiring surgery is uncommon in children. The challenge in this case was not just the size of the child's arteries, but the fact that both the left and right coronary arteries were severely diseased. The surgery involved using both internal mammary arteries (IMAs) as grafts, which is technically complex. We harvested the arteries and created new pathways to restore blood flow to the heart. This kind of double artery bypass is extremely rare in such young patients. The 5-hour procedure required meticulous precision, with surgeons using microsurgical techniques to ensure the grafts would hold and function effectively. Post-surgery imaging confirmed successful revascularisation—restoring healthy blood flow to the heart." This was the second youngest Kawasaki-related coronary artery bypass surgery performed by Dr Anil Bhan, the first being in 2008 on a 1.5-year-old child, which was at the time recognised in world literature as the youngest CABG ever done. Following the surgery, the child has shown encouraging signs of recovery. His heart function is steadily improving, and his energy levels have noticeably increased. The medical team expects his cardiac health to continue improving in the coming months.
The Hindu
5 hours ago
- The Hindu
Europe suffers its largest diphtheria outbreak in 70 years
The largest diphtheria outbreak to strike Western Europe in 70 years has been affecting vulnerable people such as migrants and the homeless since 2022, new research said Wednesday. Diphtheria is a highly contagious bacterial infection that can attack the respiratory tract and spread throughout the body, causing a sore throat, fever and other symptoms. For unvaccinated people, it can be fatal in around 30 percent of cases, and is deadlier for children, according to the World Health Organization. In 2022, there was an unusual surge in the bacteria that causes diphtheria -- Corynebacterium diphtheriae -- in several European countries, particularly among recently arrived migrants, according to a study in the New England Journal of Medicine. That year 362 cases were recorded by the European Centre for Disease Prevention and Control. Contact tracing and screening helped tamp down the outbreak, but rare infections have continued to be recorded, the researchers said. A total of 536 cases, including three deaths, have been recorded across Europe since the start of 2022. Patient samples from 10 countries showed that 98 percent of the cases were in males with an average age of 18. Almost all had recently migrated. "The outbreak, which mainly affected migrants from Afghanistan and Syria, was not the result of people being infected in their countries of origin, but during their migration journeys or in their places of accommodation in European countries," said a joint statement from France's public health agency and the Pasteur Institute. The genetic similarities between the strains seen in people from different countries suggests that there was a "recent point of contact, outside the country of origin" at the source of the outbreak, the statement added. The exact areas affected by the outbreak remains unclear. But a genetic link between the 2022 strain and the one detected in Germany this year indicates that "the bacteria continues to circulate quietly in Western Europe," the statement said. Vaccination is very effective at fending off diphtheria, and the researchers emphasised the importance of immunisation programmes for the general public. They also called for European nations to do more to ensure their most vulnerable people avoid contracting the disease. That included raising awareness of the symptoms among doctors and those in contact with migrants and the homeless, as well as increasing access to vaccines and antibiotic drugs.
